Slóvenía - slóvenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - ritonavir - filmsko obložena tableta - ritonavir 100 mg / 1 kapsula - ritonavir

Slóvenía - slóvenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - ritonavir - filmsko obložena tableta - ritonavir 100 mg / 1 kapsula - ritonavir

Evrópusambandið - slóvenska - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - velmanase alfa - alfa-mannosidosis - drugi zdravljene bolezni prebavil in presnove izdelki, - zdravljenje brez nevrološke manifestacije pri bolnikih z blago do zmerno alfa-mannosidosis.

Evrópusambandið - slóvenska - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1)orpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.

Evrópusambandið - slóvenska - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evrópusambandið - slóvenska - EMA (European Medicines Agency)

bial portela & companhia s.a. - opikapon - parkinsonova bolezen - anti-parkinsonska zdravila - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Evrópusambandið - slóvenska - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryjeva bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

Evrópusambandið - slóvenska - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.